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mendations reduced 57% the probability of uncontrolled blood pressure. Having
uncontrolled blood pressure at the baseline stage increased the probability of lack
of control in 166%, and per each unit of increase in body mass index the lack of
control increased 7%. CONCLUSIONS: CME intervention improved the medical de-
cision-making process to manage hypertension, thus increasing the probability of
hypertensive patients to have blood pressure under control.
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TREATMENT FOR DEPRESSION IN WOMEN WITH HYPERTENSION
Atkins E, Sambamoorthi U
West Virginia University, Morgantown, WV, USA
OBJECTIVES: The objective of the study was to examine rates of depression treat-
ment and variations in depression treatment by demographic, socioeconomic, ac-
cess to care, health status, and life-style characteristics among women with
hypertension. METHODS: The study design was cross-sectional, using data on
from 2006 and 2007 Medical Expenditure Panel Survey (MEPS), large-scale surveys
of families and individuals to provide nationally representative estimates of health
care use and expenditures. The study included 1304women aged 22 and older with
hypertension and depression, identified from MEPS medical condition files. Anti-
depressantswere identified fromprescription drug reports and psychotherapywas
identified from outpatient visits files. Depression treatment patterns by demo-
graphic, socioeconomic, healthcare access and health status were analyzed using
chi-square tests, logistic regression and multinomial logistic regressions. All anal-
ysis accounted for the complex design of the MEPS using SAS 9.2. RESULTS: In our
study sample, 23.9% had no depression treatment, 56.8% had antidepressant use
only, and 19.3% had psychotherapy with or without antidepressants. Among
womenwith hypertension and depression, African Americans (AOR 0.47), Latina
(AOR 0.46), and uninsured (AOR 0.39) were significantly less likely to report any
treatment for depression compared to Whites and those with private insurance.
Compared to no treatment, psychotherapy with or without antidepressants was
less likely among those with less than high school education and more likely
among women reporting fair/poor mental health. CONCLUSIONS: Nearly one-
quarter of women with hypertension did not have treatment for depression. Dis-
parities in depression treatment by race/ethnicity, health insurance, and education
status were noted. Further studies need to explore reasons for not receiving de-
pression treatment and whether such lack of treatment for depression is associ-
ated with poor health outcomes in these women.
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INSURANCE STATUS AND THE USE OF ANGIOTENSIN II RECEPTOR BLOCKERS
(ARBS) AND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS AMONG
POST-MYOCARDIAL INFARCTION (MI) PATIENTS
Kaisaeng N, Zhang J
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: To evaluate the effect of insurance status on the use of ARBs and ACE
inhibitors among post-Myocardial Infarction (MI) patients. METHODS: The 2007
full-year consolidated data from the Medical Expenditure Panel Survey (MEPS),
nationally representative survey, was used and linked with the prescribed medi-
cine data. A cross-sectional survey data analysiswas performed to evaluate the use
of ARBs and ACE inhibitors in patients diagnosed with Myocardial Infarction (MI)
and its relationship with patients’ insurance status. The outcome measures in-
cluded the binary variables of ACE inhibitor and ARB usage. A total of 464 post-MI
patients were included in the analyses by conducting multivariate logistic regres-
sion, controlling for socio-economic and demographic variables. RESULTS: Out of
464 patients with MI, 67 (14.44%) used only ARBs, 244 (52.59%) used only ACE inhib-
itors, 15 (3.23%) used both drugs, and 138 (29.74%) used neither ARBs nor ACE
inhibitors. Patients with Medicare coverage only and patients without insurance
were less likely to use ARBs, compared to patients with private insurance (adjusted
OR 0.26, p0.018; adjusted OR 0.03, p0.064, respectively). There was no significant
difference between health insurance status and use of ACE inhibitors. Further-
more, health insurance status was not significantly different among patients who
used neither ARBs nor ACE inhibitors. AmongMI patients who used both ARBs and
ACE inhibitors, patients with Medicare coverage only were less likely to use both
drugs (adjusted OR 0.02, p0.001), relative to patients with private insurance. Ad-
ditionally, patients with educational attainment of higher than college degrees
were more likely to use both drugs than those who did not finish college degrees
(adjusted OR 19.61, p0.042). CONCLUSIONS: Health insurance significantly af-
fected the usage of more expensive ARBs but not less expensive ACE inhibitors.
Policy makers need to be aware of the moral hazard arising from the insurance
coverage in drug use.
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FACTORS ASSOCIATED WITH SELECTIONS OF STATINS AMONG ELDERLY
PATIENTS
Zhao Z1, Peng X1, Bae JP1, Sponseller CA2, LeNarz LA1
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OBJECTIVES: To assess demographic and clinical factors associated with statin
selection among elderly patients. METHODS: A retrospective cohort study was
conducted to examine predictors of statin selection among patients aged 365 years,
who initiated pravastatin (PS) vs. simvastatin (SS), atorvastatin (AS), or rosuvasta-
tin (RS) between 1/1/2007 and 12/31/2007. Index statin use was defined as the first
statin claim following at least 90 days of no statin access. Multiple logistic regres-
sion models were employed to assess predictive factors of PS initiation versus
other statin initiations. RESULTS:Of 96,450 statin users identified, there were 8,165
PS initiators, 38,099 AS initiators, 11,320 RS initiators, and 38,866 SS initiators.
Compared to other statin users, a higher percentage of PS initiatorswere aged75-85
(PS: 42.3%, SS: 41.0%, AS: 41.1%, RS: 38.0%, P0.01) andmore likely to be female (PS:
56.6%, SS: 51.3%, AS: 51.5%, RS: 55.7%, P0.01). PS initiatorsweremore likely to have
atrial fibrillation (PS: 10.0%, SS: 9.4%, AS: 9.6%, RS: 8.6%, P0.01) and take warfarin
(PS: 11.7%, SS: 9.8%, AS: 10.4%, RS: 9.9%, P0.01) and triazoles (PS: 3.1%, SS: 2.4%, AS:
2.6%, RS: 2.8%, P0.01) in the baseline period. A higher percentage of PS initiators
took more than 3 unique medications 90-day prior to the index date (PS: 85.4%, SS:
81.8%, AS: 83.0%, RS: 83.9%, P0.01). After controlling for demographic and clinical
characteristics, use ofwarfarinwas associatedwith initiating PS comparedwith SS,
AS, and RS. Other predictors of PS initiation included prior history of atrial fibrilla-
tion, HIV infection and use of calcium channel blockers, ezetimibe, and fenofi-
brates over the 1-year pre-index period compared with AS and SS. CONCLUSIONS:
Patient profiles were different among PS users compared to other statin users.
Selected comorbidities and prior use of certain medications were significant pre-
dictors of PS initiation among a cohort of Medicare patients.
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PATTERNS OF STATIN PRESCRIPTION AMONG PRIVATELY INSURED
COMMERCIAL AND MEDICARE PATIENTS
Bae JP1, Peng X1, Zhao Z1, Zagar A1, Sponseller CA2, LeNarz LA1
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OBJECTIVES: In 2008, therewere currently 6 statins available in theU.S.market and
more than 193million statin prescriptionswerewritten.We sought to examine the
patterns of statin use among privately insured commercial and Medicare patients
in the U.S. METHODS: A retrospective analysis was performed using MarketScan
Commercial and Medicare data from Jan. 2008 to Dec. 2008. Two cohorts were
created: 1) the commercial cohort (CC) and 2) the Medicare cohort (MC). Statin
scripts of minimum 30 day supply were extracted from the pharmacy claims data
and individual demographic and clinical information were linked from their med-
ical and administrative records. Prescription patternswere examined and analyses
by age and genderwere performed.RESULTS:Therewere 18million and 9.8million
statin prescriptions filled by the CC and MC, respectively. In both cohorts, simva-
statin accounted for the largest share of statin prescriptions (MC: 44.1%; CC: 44.0%),
followed by atorvastatin (MC: 31.6%; CC: 31.1%), rosuvastatin (MC: 7.8%; CC: 11.2%),
pravastatin (MC: 8.1%; CC: 6.5%), lovastatin (MC: 7.4%; CC: 6.6%) and fluvastatin
(MC: 0.9%; CC: 0.6%). The majority of statin prescriptions were for generics (MC:
59.6%; CC: 57.1%).The average annual number of statin prescription per user was
9.3 for the MC and 7.6 for the CC. In the CC, 58.1% of prescriptions were filled by
male, while 50.4% of prescriptions were filled by male in the MC. Diabetic patients
accounted for 35.2% of prescriptions in the MC, and 26.8% in the CC. Milligram
dosing distributions (mean; median; mode) were for simvastatin (MC:32.1; 20;20
CC:32.9;20;40); atorvastatin (MC:24.3;20;10 CC:24.7;20;10); rosuvastatin (MC: 12.7;
10;10 CC:13.1;10;10); and pravastatin (MC:37.6;40;40 CC:38.2;40;40). CONCLUSIONS:
This analysis suggests different statin use patterns by age, gender, and insurance.
Most frequently dispensed doses were 20 mg for simvastatin, 10 mg for atorvasta-
tin and rosuvastatin, and 40 mg for pravastatin.
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COMPARISON OF DOSING PATTERNS AMONG PATIENTS INITIATING STATIN
THERAPY IN A MANAGED CARE POPULATION
Zhao Z1, Peng X1, Bae JP1, Dungey J1, Faries DE1, Sponseller CA2, Wetmore S1, Yu CY1,
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OBJECTIVES: To compare dosing patterns among patients in whom atorvastatin
(AS), simvastatin (SS), rosuvastatin (RS), or pravastatin (PS) was newly prescribed.
METHODS: Using a large US managed care database, study patients aged18 who
were newly prescribed AS, SS, RS, or PS between 10/01/2006-09/30/2007 were iden-
tified with a minimum 12 months pre- and 24 months post-index health plan
eligibility. A 6-month washout period free of use of any statin was applied to iden-
tify patients in whom statin therapy was newly prescribed. The index date was
defined as the date of the first prescription fill for statins and 4 cohortswere created
based on index statins: AS, SS, RS, or PS. Patients were followed up to 24 months
after the index date, and the average daily dose for 12 prescriptions per person,
average/median daily dose in each of the first 12 prescriptions, and the average
daily statin costs were compared among 4 cohorts. RESULTS: A total of 142,692
patientswere identified, comprised of 47,972 AS patients, 21,475 RS patients, 62,954
SS patients, and 10,291 PS patients. The average daily doses of all prescriptions
were 21.3mg for AS patients, 10.2mg for RS patients, 29.2mg for SS patients, and
34.6mg for PS patients. The average/median daily dose for the 1st and 12th pre-
scriptions were 20.8mg/20mg and 21.2mg/20mg for AS patients, 10.0mg/10mg and
10.5mg/10mg for RS patients, 28.4mg/20mg and 28.7mg/20mg for SS patients, and
32.8mg/40mg and 35.9mg/40mg for PS patients. The average daily statin costs for
the 1st and 12th prescriptions were $2.9 and $3.2 for AS patients, $2.7 and $3.1 for
RS patients, $1.5 and $0.8 for SS patients, and $1.4 and $0.9 for PS patients.
CONCLUSIONS: Patients initiating AS, RS, SS, and PS experienced little escalation
of their statin daily dosing over the 24-month follow-up period.
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OBJECTIVES: To assess demographic and clinical factors associated with statin
selection among patients in a large employer-based claims database. METHODS:
This study examined predictors of statin selection among statin users whowere 18
to 64 years old and initiated pravastatin (PS) vs. simvastatin (SS), atorvastatin (AS),
or rosuvastatin (RS) between 1/1/2007 and 12/31/2007. Index statin use was defined
as the first statin claim following at least 90 days of no statin access. Multiple
logistic regression models were employed to assess predictive factors of PS initia-
tion versus other statin initiations. RESULTS: Of the total 1,336,433 statin users
identified, there were 14,122 PS initiators, 66,156 AS initiators, 27,062 RS initiators,
and 77,180 SS initiators. Compared to other statin users, patients initiating PSwere
older (PS: 54.0, SS: 53.3, AS: 53.9, RS: 53.5, P0.01) and more likely to be female (PS:
52.3%, SS: 47.6%, AS: 45.4%, RS: 47.0%, P0.01). A higher percentage of PS initiators
had diabetes (PS: 20.1%, SS: 17.9%, AS: 17.9%, RS: 18.3%, P0.01), liver disease (PS:
2.7%, SS: 1.9%, AS: 2.1%, RS: 2.4%, P0.01), human immunodeficiency virus infec-
tion (HIV) (PS: 0.7%, SS: 0.1%, AS: 0.3%, RS: 0.3%, P0.01), and hypertension (PS:
45.1%, SS: 40.8%, AS: 41.1%, RS: 43.9%, P0.01) in the baseline period. After control-
ling for demographic and clinical characteristics, older age, female gender, history
of diabetes, liver disease, HIV, and hypertension were significant predictors of PS
initiation. Other predictors of PS initiation included use of calcium channel block-
ers, ezetimibe, fenofibrates, and protease inhibitors over the 1-year pre-index pe-
riod. Primary care physician (PCP) as the prescriber was positively associated with
initiating PS compared to RS or SS.CONCLUSIONS:The analyses indicate that older
age, female gender, presence of selected comorbidities, prior use of certain medi-
cations, and PCP as prescriber are predictors of PS initiation among working age,
commercially insured patients.
PCV91
BETA BLOCKERS AND DIURETICS USAGE IN CROATIA AND SLOVENIA DURING
A NINE-YEAR PERIOD
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OBJECTIVES: Cardiovascular diseases are the major health problem and adequate
therapy, which includes usage of beta blockers (ATC, C07) and diuretics (ATC, C03),
leads to reduction of cardiovascular morbidity andmortality. The aim of our study
was to identify and analyze changes in the usage of these drugs in Croatia and
Slovenia from 2000-2008 and to identify the rate of the generic drugs usage as well
as the average price for 1 DDD.METHODS: The data concerning consumption have
been obtained from the International Medical Statistics database for Croatia and
they are presented in defined daily doses per 1000 inhabitants per day (DDD/1000).
Financial expenditure data are presented in Euros and the average cost per DDD
was calculated for each drug group. RESULTS: The total usage of diuretics is on
average 19% higher in Croatia and continually increasing in both countries. Con-
sumption rate of furosemid among diuretics is lower in Slovenia (43.96% in 2008),
while in Croatia 67.28% (2008). The generic drugs usage is higher in Croatia during
the whole investigated period, e.g. in 2008, 87.4 % of all prescribed diuretics were
generics in Croatia, and in Slovenia 59.4%. The average price per 1 DDD was more
than twice lower in Croatia (0.08 EUR/DDD vs. 0.17 EUR/DDD in Slovenia). The beta
blockers drugs usage is 13% higher in Slovenia, but generic drugs usage is higher in
Croatia. CONCLUSIONS: Increased diuretics and beta blockers drug usage is com-
parable to worldwide trends, but drug prescribing patterns are different when
comparing both countries. Although the generic drugs usage is relatively high in
Croatia, it should be further supported and promoted. According to our investiga-
tion there is a possibility for further price reduction of diuretics and beta blockers in
Slovenia. This is important as a tool to decrease costs of healthcare systems.
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CHANGES IN THE PREVALENCE, TREATMENT AND CONTROL OF
HYPERTENSION IN GERMANY? A CLINICAL-EPIDEMIOLOGICAL EXAMINATION
OF 50,000 PRIMARY CARE PATIENTS WITH THE DETECT STUDY
Labeit A1, Klotsche J2, Pieper L2, Wehling M3, Wittchen HU2
1University of Leicester, Leicester, United Kingdom, 2Technische Universität Dresden, Dresden,
Germany, 3Universität Heidelberg - Medizinische Fakultät Mannheim, Mannheim, Germany
OBJECTIVES: To estimate 2003 point prevalence, treatment and control rates of
hypertension for different age groups of primary care attendees in Germany, to
examine factors associated with pharmacotherapy and adequate blood pressure
control and to examine whether changes have occurred in rates of treatment and
control since 2001. METHODS: Using standardized clinical diagnostic and treat-
ment appraisal forms, blood pressure levels and patient questionnaires for 55,518
participants from the DETECT study (2003) were analyzed. RESULTS: According to
physician diagnosis overall prevalence was 35.5%, according to NHANES criteria
56.0%. Among those defined by NHANES criteria, treatment and control rates were
56.0% and 20.3%, respectively. Significant predictors for receiving antihypertensive
medication were: increasing age, female sex, obesity, previous myocardial infarc-
tion and the prevalence of comorbid conditions such as CHD, dyslipidemia and
diabetes mellitus. Significant positive predictors of adequate blood pressure con-
trol were CHD and antihypertensive medication. Inadequate control was associ-
atedwith increasing age, male sex and obesity. As compared to findings from 2001,
rates of treatment and control indicate some improvement across all age groups.
CONCLUSIONS:Rates of treated and controlled hypertension according toNHANES
criteria in DETECT remain considerably low as compared to the rates of 2001,
despite consistent indications of some improvement. Hypertensive patients with
risk factors such as obesity and associated comorbidities such as CHD, dyslipide-
mia and diabetes weremore likely to receive antihypertensive drugs in accordance
with guidelines. Adequate blood pressure control was achieved in more patients
with obesity and CHD, but not those with diabetes mellitus or dyslipidemia.
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HEALTH EXPENDITURE COMPARISON OF METOPROLOL SUCCINATE VS
METOPROLOL TARTARATE
Vaidya V, Patel P
University of Toledo, Toledo, OH, USA
OBJECTIVES: To compare health care expenditures of hypertensive patients on
metoprolol tartarate (MT) andmetoprolol succinate (MS).Metoprolol, a selective -1
blocker, is available in two different salt forms in themarket-metoprolol succinate
(MS) and metoprolol tartarate (MT). Both of these salts are FDA approved for the
treatment of hypertension. Several studies have shown similar efficacies between
the two salts; however they are priced at different levels because of their pharma-
cokinetic properties. MT is the short acting salt and is given twice daily, whereas
MS is the long acting salt and is given once daily. METHODS: Two cohorts of pa-
tients usingMT andMSwere selected from 2008Medical Expenditure Panel Survey
(MEPS). Propensity score (PS) matching technique was used to balance the cohorts
on various parameters such as demographic information, insurance status and
comorbity score. Patients using MTwerematched to patients using MS on the logit
of propensity score using calipers of width equal to 0.2 of the standard deviation of
the logit of the propensity score. To estimate mean expenditure costs and 95%
confidence intervals, non parametric bootstrap sampling method was used.
RESULTS: A total of 742 patients were found to use metoprolol (MT-388, MS- 354).
After PS matching, a total of 594 patients were left in the sample for final analysis
(298 patients in each cohort). The average annual expenditure in two groups did not
differ significantly. After carrying out non parametric bootstrap sampling using
1,000 samples, MT cohort had $10,779 (95% CI: $10,682- $10,875) average annual
expenditure while MS cohort had $9,810 (95% CI: $9,810-$10,003). CONCLUSIONS:
Both the salts of Metoprolol were found have similar average annual total health-
care expenditure, however once a daily salt (MS) has higher out of pocket cost.
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ANTICOAGULANT USE, THE PREVALENCE OF BRIDGING AND RELATION TO
LENGTH OF STAY AMONG HOSPITALIZED PATIENTS WITH NON-VALVULAR
ATRIAL FIBRILLATION
Smoyer-Tomic K1, Sander S2, Siu K2, Smith DM3, Amin A4, Johnson BH1
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OBJECTIVES: ASA/AHA guidelines for stroke prevention in patients with non-val-
vular atrial fibrillation (NVAF) recommend anticoagulant (AC) therapy with a vita-
min K antagonist (e.g., warfarin) for patients without hemorrhagic contraindica-
tion. Bridging with low molecular weight heparin (LMWH) was recently added to
these guidelines (Class IIa), butwith little supportive evidence (Level of Evidence C).
Little is known about the use of AC therapy in the inpatient setting and how it
relates to hospital length of stay (LOS).METHODS: Patientswith anNVAF discharge
diagnosis between 7/1/04-9/30/09 were identified from administrative claims data
representing over a hundred US hospitals. Inpatient AC use by drug type was re-
ported to identify patients receiving warfarin alone and in combination with
LMWH/pentasaccharide (PS) or unfractionated heparin (UFH), indicative of bridg-
ing. LOS was measured and reported by AC combinations. Non-parametric statis-
tical tests were used to compare LOS among patients receiving warfarin only to
thosewith bridge therapy.RESULTS:Of 6340NVAFpatients, 76% received inpatient
AC therapy, with 3037 (48%) receiving warfarin. Of patients receiving warfarin, 64%
were bridged with another AC. LMWH/PS was themost common bridge agent (45%
of all bridged patients), followed byUFH (36%), and by LMWH/PS andUFH combined
(18%). The mean LOS for patients receiving bridge therapies was 6.3 days (SD6.1)
compared to 4.2 days (SD 3.1) for warfarin alone, p.0001. By bridging drug type,
mean LOS was 5.6 days (SD5.3) for LMWH/PS; 6.0 days (SD4.9) for UFH, and 8.4
days (SD8.4) for LMWH/PS and UFH. CONCLUSIONS: Less than half of all NVAF
patients receivedwarfarinwhile hospitalized. Among those takingwarfarin, bridg-
ing with other anticoagulants was common and was associated with longer LOS
than patients receiving warfarin alone.
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USING COMPUTERIZED PHYSICIAN ORDER ENTRY OF ANTI-HYPERTENSIVE
MEDICATIONS TO CONNECT INDICATIONS WITH PRESCRIBING AND IMPROVE
PROBLEM LIST DOCUMENTATION
Galanter W, Walton S, Falck S, Rosencranz H, Adimadhyam S
University of Illinois Chicago, Chicago, IL, USA
OBJECTIVES: Electronic Medical Records often lack accurate problem lists. The
objectives of this studywere to examine if alerts requesting indication information
during order entry of medications used to treat a common disease, hypertension,
can improve problem lists. METHODS: Inpatient orders generated by previously
implemented clinical decision support (CDS) in an academic hospital using CPOE
were reviewed. CDSwas developed for classes of antihypertensive and 3 additional
diagnoses: CHF, benign prostatic hypertrophy and nephropathy. Five logical med-
ication groups were developed. A random sample of 250 charts were collected for
each medication group and reviewed by physicians to determine alert yield and
added problem accuracy. The accuracy and yield (problems added per order) were
analyzed across the medication groups, clinician types, and clinical venues.
RESULTS: Preliminary results obtained from the group of medications that only
treat HTN and no other diagnoses (HTN group) showed an accuracy of additions to
the problem list of 92% and the yield, was 76%. For the group of medications which
treated HTN and CHF (CHF group), the accuracy and yield were lower, 81% and 62%
respectively. Looking at the HTN group alone, the accuracy was 100% for attending
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